Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) has shared an update.
Algorae Pharmaceuticals has signed an exclusive licensing agreement with Sakar Healthcare to launch five generic oncology medicines in Australia and New Zealand, marking its first commercial presence in these markets. This strategic move complements Algorae’s ongoing R&D initiatives and leverages Sakar’s manufacturing capabilities, aiming to enhance patient access to high-quality oncology treatments and position Algorae for long-term growth.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company that focuses on discovering and developing drug synergies for unmet medical needs. The company utilizes its proprietary AI platform, AlgoraeOS, to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into the clinic and is publicly traded on the Australian Stock Exchange.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.66M
Learn more about 1AI stock on TipRanks’ Stock Analysis page.